281 related articles for article (PubMed ID: 16518693)
1. Natural selection and mammalian BRCA1 sequences: elucidating functionally important sites relevant to breast cancer susceptibility in humans.
Burk-Herrick A; Scally M; Amrine-Madsen H; Stanhope MJ; Springer MS
Mamm Genome; 2006 Mar; 17(3):257-70. PubMed ID: 16518693
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Pavlicek A; Noskov VN; Kouprina N; Barrett JC; Jurka J; Larionov V
Hum Mol Genet; 2004 Nov; 13(22):2737-51. PubMed ID: 15385441
[TBL] [Abstract][Full Text] [Related]
3. Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes.
Ramirez CJ; Fleming MA; Potter JD; Ostrander GK; Ostrander EA
Oncogene; 2004 Mar; 23(9):1780-8. PubMed ID: 15001988
[TBL] [Abstract][Full Text] [Related]
4. Understanding missense mutations in the BRCA1 gene: an evolutionary approach.
Fleming MA; Potter JD; Ramirez CJ; Ostrander GK; Ostrander EA
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1151-6. PubMed ID: 12531920
[TBL] [Abstract][Full Text] [Related]
5. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
Yang Y; Swaminathan S; Martin BK; Sharan SK
Hum Mol Genet; 2003 Sep; 12(17):2121-31. PubMed ID: 12915465
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.
Pettigrew C; Wayte N; Lovelock PK; Tavtigian SV; Chenevix-Trench G; Spurdle AB; Brown MA
Breast Cancer Res; 2005; 7(6):R929-39. PubMed ID: 16280041
[TBL] [Abstract][Full Text] [Related]
7. Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites.
Khan MM; Rydén AM; Chowdhury MS; Hasan MA; Kazi JU
Gene; 2011 Sep; 483(1-2):29-35. PubMed ID: 21640173
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
9. Beta-defensin evolution: selection complexity and clues for residues of functional importance.
Semple CA; Taylor K; Eastwood H; Barran PE; Dorin JR
Biochem Soc Trans; 2006 Apr; 34(Pt 2):257-62. PubMed ID: 16545088
[TBL] [Abstract][Full Text] [Related]
10. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
[TBL] [Abstract][Full Text] [Related]
11. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
[TBL] [Abstract][Full Text] [Related]
12. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
13. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
14. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
15. Missense mutations in the BRCT domain of BRCA-1 from high-risk women frequently perturb strongly hydrophobic amino acids conserved among mammals.
Figge MA; Blankenship L
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):1037-41. PubMed ID: 15184261
[TBL] [Abstract][Full Text] [Related]
16. [Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers].
Zhang HT; Lu YF; Zeng J; Lin J; Liao QH; Wan FQ
Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):480-2. PubMed ID: 17686308
[TBL] [Abstract][Full Text] [Related]
17. Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study.
Huttley GA; Easteal S; Southey MC; Tesoriero A; Giles GG; McCredie MR; Hopper JL; Venter DJ
Nat Genet; 2000 Aug; 25(4):410-3. PubMed ID: 10932184
[TBL] [Abstract][Full Text] [Related]
18. Classification of BRCA1 missense variants of unknown clinical significance.
Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
[TBL] [Abstract][Full Text] [Related]
19. Molecular evolution of amelogenin in mammals.
Delgado S; Girondot M; Sire JY
J Mol Evol; 2005 Jan; 60(1):12-30. PubMed ID: 15696365
[TBL] [Abstract][Full Text] [Related]
20. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Dobricić J; Branković-Magić M; Filipović S; Radulović S
Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
